Blood Podcast Episode Summary

Episode Title: Review Series on the Structural Underpinnings of Hemostatic Plugs and Thrombotic Occlusions
Date: February 26, 2026
Host: American Society of Hematology
Moderator: Dr. Tom Martell, Duke University
Guests & Contributors:

• Dr. Alyssa Wolberg (University of North Carolina)
• Dr. Jonas Emslie (University of Nottingham)
• Dr. John Wiesel (with Rustem Litvinov)

Episode Overview

This special bonus episode of the Blood Podcast introduces a comprehensive review series on the molecular and structural basis of hemostatic plugs and thrombotic occlusions, as newly published in Blood, the journal of the American Society of Hematology. Moderator Dr. Tom Martell guides a conversation with several contributing authors who discuss advances in understanding clot composition, formation, and function across diverse vascular beds, and how this evolving knowledge suggests novel opportunities for intervention in bleeding and thrombosis.

Key Discussion Points & Insights

1. Scope of the Review Series

(00:26-02:57)

• The series examines the complete formation of hemostatic plugs, encompassing cells, proteins, and molecules.
• Reviews the differences in thrombus structure across various vascular beds (e.g., venous vs. arterial).
• Focuses on both core components (like platelets, Factor XIII, contact system) and their interactions with inflammation.
• Includes an overview of novel strategies for hemostasis, specifically outside hospital settings.

“This one looks at the complete formation of hemostatic plugs, the cells, the proteins, the other molecules that are involved… and how when things go awry, you may have a thrombotic occlusion.”
— Dr. Tom Martell (00:44)

2. Deep Dive: Factor XIII and Clot Stability

With Dr. Alyssa Wolberg (02:57-04:40; 07:51-10:26; 14:41-17:22)

• Role of Factor XIII: Not just another coagulation enzyme; acts more as a “glue” than a protease.
• Crucial for cross-linking fibrin, stabilizing clots, and integrating cellular elements (RBCs, platelets).
• Diseases involving Factor XIII impact both hemostasis and thrombosis, with notable ties to inflammatory and liver pathologies.
• Discusses the therapeutic window: patients can tolerate low Factor XIII; thus, selective inhibition might limit unwanted clots without excessive bleeding.
• Speculative Therapies: Modulating Factor XIII activity/function or timing could restrict clot size and occlusiveness—a promising avenue to lower thrombosis risk minus the bleeding seen with classic anticoagulants.

"It's actually unofficially known as a meat glue, which makes it really, really unique. And its role then in how it holds together the clots and then the downstream implications of that…"
— Dr. Alyssa Wolberg (03:31)

“Patients with factor 13 deficiency usually don't have any bleeding until they get severely low, essentially non-detectable factor 13... that points to the idea that there may be an interesting window in which we can safely operate and manipulate... maybe not just factor 13 levels, but its actual biochemical functions in even a more elegant fashion."
— Dr. Alyssa Wolberg (07:51)

3. The Contact System & Inflammation

With Dr. Jonas Emslie (04:52-06:56; 11:06-13:51)

• The contact system involves Factor XII, Factor XI, prekallikrein, and high molecular weight kininogen.
• Though less essential for hemostasis, it crucially links coagulation and inflammation.
• Much is known structurally about individual zymogens; less about their macromolecular assemblies and substrate targeting.
• Genetic polymorphisms (notably in kininogen) may explain why some individuals have heightened inflammatory responses to thrombosis.
• Targeting Factor XI: dual inhibitors (e.g., of Factor XI and prekallikrein) are being explored, given the compensatory mechanisms and interplay with inflammatory pathways. Caution is advised due to system redundancy—knocking out one factor may upregulate another.

“Both factor 11 and precalicorine are homologous. They both cleave factor 9 part of the intrinsic pathway. And although precalicorine is the main driver for inflammation and bradykinin formation, factor 11 also seems to drive these inflammatory processes.”
— Dr. Jonas Emslie (12:54)

"The big takeaway was that we understand quite a lot about the structure of the zymogens... but we really know very little about the higher rules done multiprotein complexes of contact system and very little about the molecular detail of substrate engagement."
— Dr. Jonas Emslie (06:36)

4. Structural Differences in Clots: Arterial vs. Venous

Panel Discussion (13:51-17:22; 17:55-26:12)

• Arterial clots = platelet-rich ("white" clots, but actually pink/light, less RBC content)
• Venous clots = red cell-rich ("red" clots)
• Factor XIII and overall composition influence the structure, stability, and pharmacologic response of clots in different beds.
• The efficiency of various antithrombotic drugs underscores the real structural and functional differences between clot types.
• Functional implications: Factor XIII is more critical in forming stable, occlusive venous clots than arterial ones, with clot contraction timing affecting lytic potential.

“Arterial clots seem to form even if there's no factor 13 there. But the ability of factor 13 to cross link and really stabilize those clots can vastly affect whether those arterial clots… clear or can undergo thrombolysis.”
— Dr. Alyssa Wolberg (15:45)

5. The Architecture of Thrombi: New Findings

With Dr. John Wiesel (17:55-26:12)

• Comprehensive observation and analysis of human thrombi reveals dynamic changes over time (e.g., in myocardial infarction: initial platelet dominance, with increasing fibrin and decrease in platelets as clot ages).
• Clot contraction is central: platelets pull on fibrin, compressing RBCs into polyhedral shapes (termed polyhedrocytes).
• Thrombi are tightly packed, with little free space, due to contraction.
• Fibrin’s unique mechanics: molecules can unfold upon strain, featuring remarkable resilience; fibrin is also an “equilibrium polymer”—molecules/oligomers can dissociate and reassociate prior to full crosslinking by Factor XIII.
• Exhaustion of platelets in chronic thrombotic patients impairs contraction, making thrombi more obstructive and prone to embolization.
• New experimental systems: human induced pluripotent stem cell-derived megakaryocytes enable genetic studies of platelet function—promising for future basic research.

“We found that in thrombotic patients, platelets become continuously partially activated and they become exhausted. So the ATP levels go down, the mitochondrial membrane potential decreases, and the platelets become refractory…”
— Dr. John Wiesel (22:57)

“What happens is that platelets pull on fibrin and platelets make a kink in the fibrin fiber and pull it towards the platelets or the platelet aggregates and the fibrin agglomerates around the platelets, and then platelets pulling on fibrin compresses the red blood cells so that they change shape from being biconcave to being polyhedral. This is something we see in nearly all human thrombi.”
— Dr. John Wiesel (19:28)

6. Bridging Models and Human Disease

(26:12-27:17)

• Mouse and in vitro models broadly replicate the sequence of plug formation in humans, but important differences remain.
• Future challenge: improving the translational relevance between animal models and human pathophysiology.

“One of the challenges… is to be able to understand how we go from those mouse models to what we see in human thrombi.”
— Dr. John Wiesel (26:52)

Notable Quotes & Memorable Moments

• “Instead of cleaving proteins, [Factor XIII] glues them together. It’s actually unofficially known as a meat glue, which makes it really, really unique.”
  — Dr. Alyssa Wolberg (03:31)

• “There is still a big mystery in the field in terms of what the precise membrane, where all the contact factors are assembled and the molecular mechanisms of how the enzymes become activated.”
  — Dr. Jonas Emslie (05:46)

• “We found that in thrombotic patients, platelets become continuously partially activated and they become exhausted... and the platelets become refractory, so they're less able to respond. And this impaired contraction or retraction has at least three pathogenic consequences...”
  — Dr. John Wiesel (22:57)

Important Timestamps & Segments

• 00:26: Dr. Martell introduces the review series structure and goals
• 02:57: Dr. Wolberg details Factor XIII’s role
• 04:52: Dr. Emslie overviews the contact activation pathway
• 07:51: Dr. Wolberg discusses therapeutic implications of Factor XIII manipulation
• 11:06: Dr. Emslie on inflammatory genetic variants and clinical implications
• 13:51: Differences in arterial vs. venous clots
• 17:55: Dr. Wiesel provides a comprehensive overview of thrombus structure
• 22:57: Platelet exhaustion and pathologic sequelae
• 25:48: Comparing pathologic thrombosis and normal hemostasis structure
• 26:52: Translational challenges in the field

Takeaway

This episode provides a detailed, multidimensional look at the structural biology of blood clotting, from molecular assembly to clinical implications for bleeding and thrombosis management. The review series marshals new insights on Factor XIII, the contact system, and the architecture of thrombi, bringing together basic science, translational potential, and provocative questions about the future of hemostasis and thrombosis therapy.